Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab DDI Study in Atopic Dermatitis
NCT06686628Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoints: Area Under the Curve for CYP substrates and Area Under the Curve from time zero to the last quantifiable concentration for CYP substrates. Started Nov 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06686628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686628.